Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment

NCT02540876 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02540876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02540876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment
Lead sponsor
University of Chicago
Phase
Phase 1
Overall status
Completed
Start date
September 8, 2015
Completion date
February 8, 2019
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm, solid neoplasm, unresectable malignant neoplasm